Page 150 - 2022_01-Haematologica-web

A.R. Mato et al.
References
1. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 (Suppl 5):v78-84.
2. Siegel RL, Miller KD, Jemal A. Cancer statis- tics, 2017. CA Cancer J Clin. 2017;67(1):7- 30.
3. Dreger P. Allotransplantation for chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2009:602-609.
4. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines): Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 2.2019. NCCN website. www.nccn.org/professionals/physician_gls/ pdf/cll.pdf. Published October, 2018. Accessed August, 2019.
5. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202- 208.
6. Brown JR. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malig Rep. 2013;8(1):1-6.
7. Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627- 644.
8. Montero J, Letai A. Why do BCL-2 inhibitors work and where should we use them in the clinic? Cell Death Differ. 2018;25(1):56-64.
9. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236.
10. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768-778.
11. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lym- phocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973-1980.
12. Roberts AW, Seymour JF, Eichhorst B, et al. Pooled multi-trial analysis of venetoclax effi- cacy in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2016;128(22):3230.
13. Jones J, Choi MY, Mato AR, et al. Venetoclax (VEN) Monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to Ibrutinib or Idelalisib. Blood. 2016;128(22):637.
14.Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lympho- cytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062-2067.
15. Maddocks KJ, Ruppert AS, Lozanski G, et al.
Etiology of ibrutinib therapy discontinua- tion and outcomes in patients With chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80-87.
16. Barr PM, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129(19):2612-2615.
17. Jain P, Thompson PA, Keating M, et al. Long- term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123(12):2268-2273.
18. O'Brien SM, Byrd JC, Hillmen P, et al. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: phase 3 analysis. Am J Hematol. 2019;94(5):554-562.
19. Ahn IE, Basumallik N, Tian X, et al. Clinically-indicated ibrutinib dose interrup- tions and reductions do not compromise long-term outcomes in CLL. Blood. 2019;133(22):2452-2455.
20. Sandoval-Sus JD, Chavez JC, Dalia S, et al. Outcomes of patients with relapsed/refrac- tory chronic lymphocytic leukemia after ibrutinib discontinuation outside clinical tri- als: a single institution experience. Blood. 2015;126(23):2945.
21. Thompson PA, Levy V, Tam CS, et al. The impact of atrial fibrillation on subsequent survival of patients receiving ibrutinib as treatment of chronic lymphocytic leukemia (CLL): An international study. Blood. 2016; 128(22):3242.
22. Akhtar OS, Torka P, Bhat SA, et al. Disease progression on ibrutinib therapy is associat- ed with a poor clinical outcome in chronic lymphocytic leukemia (CLL) patients man- aged in standard clinical practice. Blood. 2017;130(Suppl 1):S5350.
23. Follows GA, CLL Forum UK. Ibrutinib for relapsed/refractory CLL: an update of the UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2017;35(S2):238- 239.
24. Rhodes J, Barr PM, Ujjani CS, et al. The impact of front-line ibrutinib dose reduction and interruption on outcomes in chronic lymphocytic leukemia (CLL) patients. Blood. 2017;130(Suppl 1):S4313.
25. Sharman JP, Black-Shinn JL, Clark J, et al. Understanding ibrutinib treatment discon- tinuation patterns for chronic lymphocytic leukemia. Blood. 2017;130(Suppl 1):S4060.
26. Winqvist M, Andersson P-O, Asklid A, et al. Real-world results on ibrutinib in relapsed/refractory CLL: 30-month follow- up of 95 Swedish patients treated in a com- passionate use program. HemaSphere. 2018;2(Suppl 1):S128-129.
27. Hampel PJ, Ding W, Call TG, et al. Rapid disease progression following discontinua- tion of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. Leuk Lymphoma. 2019;60: (11):2712-2719.
28. Williams AM, Baran AM, Casulo C, et al. Ibrutinib dose adherence and therapeutic efficacy in non-Hodgkin lymphoma: a sin- gle-center experience. Clin Lymphoma Myeloma Leuk. 2019;19(1):41-47.
29.Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax–rituximab in relapsed or refrac- tory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107-1120.
30.Seymour JF, Kipps TJ, Eichhorst BF, et al. Four-year analysis of Murano study con- firms sustained benefit of time-limited vene- toclax-rituximab (VenR) in relapsed/refrac- tory (R/R) chronic lymphocytic leukemia (CLL). Blood. 2019;134(Suppl 1):S355.
31.Lew TE, Anderson MA, Lin VS, et al. Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attain- ment plateaus after 24 months. Blood Adv. 2020;4(1):165-173.
32. Mato AR, Tam CS, Allan JN, et al. Disease and patient characteristics, patterns of care, toxicities, and outcomes of chronic lympho- cytic leukemia (CLL) patients treated with venetoclax: A multicenter study of 204 patients. Blood Adv. 2017;130(Suppl 1):S4315.
33. Eyre TA, Kirkwood AA, Gohill S, et al. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. Br J Haematol. 2019;185(4):656-669.
34. Roeker LE, Fox CP, Eyre TA, et al. Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice. Clin Cancer Res. 2019;25(14):4264-4270.
35. Brown JR, Ghia P, Jones JA, et al. Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment. J Clin Oncol. 2016;34(Suppl):S7531.
36. Thompson PA, Stingo F, Keating MJ, et al. Outcomes of patients with chronic lympho- cytic leukemia treated with first-line idelalis- ib plus rituximab after cessation of treat- ment for toxicity. Cancer. 2016;122(16): 2505-2511.
37. Bange E, Nabhan C, Brander DM, et al. Real- world evidence for durable treatment responses after toxicity related discontinua- tion of idelalisib. Blood. 2017;130(Suppl 1):S4325.
38. Ma S, Chan RJ, Ye W, et al. Survival out- comes following idelalisib interruption in the treatment of relapsed or refractory indo- lent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Blood. 2018;132 (Suppl 1):S3149.
39. Flinn I, Montillo M, Illés Á, et al. Effect of dose modifications on response to duvelisib in patients with relapsed/refractory (R/R) CLL/SLL in the DUO trial. J Clin Oncol. 2019;37(Suppl 15):S7523.
142
haematologica | 2022; 107(1)